All > Hnscc > Head And Neck Cancer

SGN-B6A for Esophageal Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Esophageal Cancer+25 MoreSGN-B6A - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study whether a drug called SGN-B6A is safe for people with solid tumors, what its side effects are, and whether it works to treat cancer.

Eligible Conditions
  • Esophageal Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Non-small Cell Lung Cancer
  • Stomach Tumors
  • Non-Small Cell Lung Cancer
  • Ovarian Tumors
  • Pancreatic Cancer
  • HER2 Negative Breast Cancer
  • Bladder Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Cervical Cancer
  • Squamous Cell Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Magnetic Resonance Imaging
1
GVHD prophylaxis regimen
1
IFX-1

Study Objectives

9 Primary · 12 Secondary · Reporting Duration: Up to approximately 3 years

Year 3
Apparent terminal elimination half-life (t1/2)
Area under the concentration-time curve (AUC)
Concentration at the end of infusion (Ceoi)
Maximum observed concentration (Cmax)
Number of participants with DLTs
Number of participants with Grade 3 or higher AEs
Number of participants with adverse events (AEs)
Number of participants with antidrug antibodies
Number of participants with antidrug antibodies (ADAs)
Number of participants with dose-limiting toxicities (DLTs)
Number of participants with serious AEs
Number of participants with treatment-emergent adverse events (AEs)
Number of participants with treatment-related AEs
Number of patients with laboratory abnormalities
Time to maximum observed concentration (Tmax)
Trough concentration (Ctrough)
Day 21
Number of participants with a DLT at each dose level
Year 3
Duration of objective response (DOR)
Objective response rate (ORR) per RECIST v1.1
Overall survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Magnetic Resonance Imaging
1
GVHD prophylaxis regimen
2
IFX-1

Trial Design

1 Treatment Group

SGN-B6A
1 of 1

Experimental Treatment

355 Total Participants · 1 Treatment Group

Primary Treatment: SGN-B6A · No Placebo Group · Phase 1

SGN-B6A
Drug
Experimental Group · 1 Intervention: SGN-B6A · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 3 years

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
185 Previous Clinical Trials
61,188 Total Patients Enrolled
Natalya Nazarenko, MDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
375 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have histologically or cytologically confirmed metastatic or unresectable solid malignancy.
You have an indication for a blood test.
You have non-small cell lung cancer (NSCLC).
You have HER2-negative advanced breast cancer.
You have a pancreatic adenocarcinoma.

Who else is applying?

What state do they live in?
Arkansas100.0%
How old are they?
65+100.0%
What site did they apply to?
MD Anderson Cancer Center / University of Texas100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top